NEWS HIGHLIGHTSMedia Articles Related to Diprolene AF (Betamethasone Topical)
Atopic Dermatitis
Source: MedicineNet mupirocin Specialty [2008.06.03]
Title: Atopic Dermatitis
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 6/3/2008
Does Your Job Make You Itch And Wheeze?
Source: Allergy News From Medical News Today [2009.11.11]
Occupational contact dermatitis and asthma are two of the most common work-related health issues facing workers worldwide, according to experts presenting the latest research at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla. "In many countries, occupational contact dermatitis ranks first among occupational diseases," said Donald Belsito, M.D.
Published Studies Related to Diprolene AF (Betamethasone Topical)
Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. [2009.07]
BACKGROUND: Current topical therapies for scalp psoriasis are difficult or unpleasant to apply, resulting in decreased adherence and efficacy. OBJECTIVES: To compare the efficacy and safety of once-daily treatment with a combination of calcipotriol 50 microg g(-1) plus betamethasone 0.5 mg g(-1) (as dipropionate) (Xamiol; LEO Pharma A/S, Ballerup, Denmark) and twice-daily calcipotriol 50 microg mL(-1) scalp solution in patients with scalp psoriasis... CONCLUSIONS: A once-daily combination of calcipotriol plus betamethasone dipropionate was significantly more effective and better tolerated than twice-daily calcipotriol scalp solution in the treatment of scalp psoriasis.
A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. [2009.01]
BACKGROUND: There is a need for new treatments for scalp psoriasis, as many topical treatments are cosmetically unacceptable and difficult to apply, resulting in poor compliance. OBJECTIVES: To compare the efficacy and safety of a new, once-daily, two-compound scalp formulation (Xamiol; LEO Pharma A/S, Ballerup, Denmark) containing calcipotriol 50 microg g(-1) plus betamethasone 0.5 mg g(-1) (as dipropionate), with the active ingredients as single compounds in the same vehicle... CONCLUSIONS: The two-compound scalp formulation was well tolerated and more effective in the treatment of scalp psoriasis than either of its individual components in the same vehicle.
Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. [2009.01]
Topical corticosteroids are widely used in the treatment of psoriasis. This study was conducted to compare the efficacy and safety of clobetasol propionate (CP) 0.005% spray to calcipotriene 0.005%-betamethasome diproprionate 0.064% (C-BD) ointment in patients with moderate to severe plaque psoriasis...
A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo. [2008.11]
BACKGROUND: Among all the topical immunomodulators, vitiligo's mainstay therapy includes topical corticosteroids. Many other non-immune theories have also been suggested for vitiligo's pathogenesis, but the role of oxidative stress has gained more importance in recent years. OBJECTIVE: To compare the effect of topical 0.05% betamethasone vs. catalase/dismutase superoxide (C/DSO). STUDY DESIGN: Randomized, matched-paired, double-blind trial. SETTING: Dermatology Section, University of Antioquia, Medellin, Colombia. SUBJECTS: Patients (aged > 18 years or between 12 and 18 years) with parent's informed consent, with stable or active bilateral vitiligo. INTERVENTION: Topical 0.05% betamethasone or C/DSO... CONCLUSIONS: Few studies have described objective methods to evaluate repigmentation among vitiligo patients. Digital morphometry provides an objective assessment of repigmentation in vitiligo. Objective vitiligo repigmentation with topical C/DSO at 10 months is similar to topical 0.05% betamethasone. Although a mild adverse effect was related to the use of C/DSO, such finding was not severe enough to discontinue treatment.
A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. [2008.09]
BACKGROUND: New topical treatments in scalp psoriasis are needed because many current topical treatments are disliked by patients and associated with poor compliance. OBJECTIVE: To compare the efficacy and safety of once-daily, two-compound scalp formulation containing calcipotriene plus betamethasone dipropionate with the individual components in the same vehicle and the vehicle alone... CONCLUSION: Calcipotriene plus betamethasone dipropionate scalp formulation was more effective than either of the individual components or the vehicle alone.
Clinical Trials Related to Diprolene AF (Betamethasone Topical)
Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis [Completed]
Patients will receive either a gel containing both calcipotriene plus betamethasone or gel
with no active ingredients as treatment for their scalp psoriasis for 8 weeks. After this
time all patients will receive the gel containing both calcipotriene and betamethasone for 44
weeks. In addition, patients will receive an ointment containing both calcipotriene plus
betamethasone as treatment for their psoriasis of the trunk and limbs for 52 weeks.
The objective is to study the short-term efficacy of the gel, and the short and long-term
safety of the gel and the ointment.
Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus [Completed]
Discoid lupus erythematosus lesions are commonly treated with corticosteroids, but
corticosteroids may induce side effects such as thinning of the skin or scarring. Therefore,
an alternative medication with the same efficacy, but without the side-effects is sought
after.
Pimecrolimus is a newer drug specially designed to treat inflammatory diseases of skin. Its
efficacy in treating discoid lupus erythematosus has not been studied extensively yet.
However studies performed till now show promising results. Long-term topical use of this
medication has not shown any serious side-effects in other skin diseases.
In this study we aimed at comparing pimecrolimus efficacy with that of a common therapeutic
choice, betamethasone valerate 0. 1% cream, to see if pimecrolimus can be used as an
alternative medication in treating discoid lupus erythematosus.
Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM1) [Recruiting]
This is a parallel-group, randomized, active-controlled, double-blind, Phase 4 trial
comparing three creams in the treatment of impetiginous eczema:
- Arm A: QUADRIDERME® cream (betamethasone diproprionate, clotrimazole and gentamicin
sulfate)
- Arm B: Combination of betamethasone diproprionate cream and gentamicin sulfate cream
- Arm C: Betamethasone diproprionate cream
At 7 sites, in Portugal, a total of 207 subjects will be randomized using a 1: 1:1
randomization ratio to receive one of the three possible treatments for a maximum period of
28 days or until 5 days after total remission of the signs and symptoms, but never more than
28 days. Assessments will be made of level of improvement of the target area in each
treatment group, number of days for total remission, and safety profile.
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis [Completed]
The purpose of the study is to evaluate whether once daily topical treatment for up to 8
weeks of calcipotriol 50 mcg/g plus betamethasone 0. 5 mg/g (as dipropionate) gel is safe and
more effective than betamethasone 0. 5 mg/g (as dipropionate) in the gel vehicle and
calcipotriol 50 mcg/g in the gel vehicle in patients with scalp psoriasis.
The primary response criterion is the number of patients with absence of disease and very
mild disease after 8 weeks of treatment.
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris [Completed]
The objective of the study is to compare the use of calcipotriol plus betamethasone
dipropionate gel with betamethasone dipropionate in the gel vehicle, calcipotriol in the gel
vehicle and the gel vehicle alone when used in patients with psoriasis vulgaris on the trunk
and/or limbs. Patients will be treated once daily for up to 8 weeks.
The primary response criterion is the number of patients with controlled disease at week 8.
|
